Incode Technologies has released its Independent Adversarial Penetration Testing Report, which shows zero mobile bypasses on biometric testing by cybersecurity firm SocialProof Security, using attacks ...

Interac is expanding its identity verification capabilities through a partnership with Incode Technologies that will add advanced liveness, deepfake and injection-attack detection to its document ...

Liveness detection software from Incode has passed presentation attack detection (PAD) evaluations to iBeta’s Level 3 on both iOS and Android devices, making it the first liveness vendor with ...

Deepfakes are evolving and are no longer confined to misinformation campaigns or viral media manipulation. Most security teams already understand the deepfake problem; however, the more urgent shift ...

[OSEN = Kim Chaeyeon, reporter] Kim Jaejoong’s first produced boy group has officially thrown its hat into the ring in the music industry. Incode Entertainment (hereinafter Incode) confirmed the debut ...

Leaders like Goldman Sachs' David Solomon say experience trumps everything in business—including brains. But Ricardo Amper, the founder and CEO of $1.25 billion software company Incode Technologies, ...

Deepfakes have evolved far beyond internet curiosities. Today, they are a potent tool for cybercriminals, enabling sophisticated fraud across onboarding, account recovery, partner verification and ...

Incode will contribute biometrics to improve the identity security and fraud protection of the U.S. government’s Login.gov platform. The face biometrics provider is a subcontractor to Diamond Capture ...

Incode Technologies has launched a new biometrics product to detect and block deepfakes and injection attacks, as agentic AI floods the tech landscape with new threat vectors. A release says Deepsight ...

(MENAFN- EIN Presswire) EINPresswire/ -- GENinCode US Inc the Irvine based predictive genetics company focused on the prevention of coronary heart disease (“CHD” or“Heart Disease”) and risk assessment ...

GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of coronary heart disease ("CHD" or "Heart Disease") and risk assessment of ovarian cancer, announces ...